C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix

Lancet. 1987 Apr 4;1(8536):761-3. doi: 10.1016/s0140-6736(87)92795-4.

Abstract

Expression of the c-myc gene was studied by northern blot and slot blot hybridisation in 72 specimens of stage I or II squamous cell carcinoma of the uterine cervix. In 25 of the 72 tumours c-myc proto-oncogene was overexpressed (ie, at levels 4-20 times higher than in normal tissues). Patients whose tumours showed c-myc overexpression had an eight-fold greater incidence of early relapse than the other patients (p = 0.001). The 18-month relapse-free survival rates were, respectively, 49% and 90% for these two groups of patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Squamous Cell / diagnosis*
  • Carcinoma, Squamous Cell / genetics
  • Female
  • Humans
  • Middle Aged
  • Nucleic Acid Hybridization
  • Prognosis
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins / analysis*
  • Proto-Oncogene Proteins c-myc
  • Proto-Oncogenes*
  • RNA, Neoplasm / analysis
  • Uterine Cervical Neoplasms / diagnosis*
  • Uterine Cervical Neoplasms / genetics

Substances

  • MAS1 protein, human
  • Proto-Oncogene Mas
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-myc
  • RNA, Neoplasm